Acute Lymphoblastic Leukemia

A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia/lymphoblastic lymphoma who are hypersensitive to E. coli-derived asparaginases was announced at the 2020 ASCO Virtual Scientific Program.

Trends in favor of better clinical outcomes were observed for those on-trial in this retrospective matched cohort study of patients with cancer who were treated on a phase III clinical trial compared with those who received standard therapy and/or were off trial.

This study found that the consumption of antioxidants through dietary intake was correlated with reduced rates of infection or mucositis, with no increased risk of relapse or reduced survival.